Curis (CRIS) Reports Encouraging Emavusertib Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)
June 4, 2022 9:00 AM EDTTakeAim Lymphoma data for the combination of emavusertib plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses
Potential for overcoming ibrutinib resistance demonstrated with a complete response in a patient who had prior treatment with ibrutinib
TakeAim Leukemia data, top-line data previously released in January, highlight emavusertib's single-agent activity in heavily pretreated AML and HR-MDS patients
LEXINGTON, Mass., June 4, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:... More
